Health Policies

35 Items

All Items

  • Analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines

    José Manuel Martínez-Sesmero, Borja Smith, Julen Madurga
    68-72
    DOI: https://doi.org/10.33393/grhta.2022.2366

  • How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality

    Pierluigi Russo
    31-35
    DOI: https://doi.org/10.33393/grhta.2022.2350

  • Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

    Roberto Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi
    30
    DOI: https://doi.org/10.33393/grhta.2022.2383

  • Real-world data: how they can help to improve quality of care

    Giovanni Corrao, Giovanni Alquati, Giovanni Apolone, Andrea Ardizzoni, Giuliano Buzzetti, Giorgio W. Canonica, Pierfranco Conte, Elisa Crovato, Francesco Damele, Carlo La Vecchia, Aldo P. Maggioni, Alberto Mantovani, Michele Marangi, Walter Marrocco, Andrea Messori, Alessandro Padovani, Alessandro Rambaldi, Walter Ricciardi, Francesco Ripa di Meana, Federico Spandonaro, Valeria Tozzi, Giuseppe Mancia
    134-139
    DOI: https://doi.org/10.33393/grhta.2021.2286

  • New drug pricing criteria in Italy: considerations and proposals to support value and innovation

    Francesca Patarnello, Federico Villa
    131-133
    DOI: https://doi.org/10.33393/grhta.2021.2207

  • Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?

    Claudio Jommi, Antonio Addis, Nello Martini, Elena Nicod, Marcello Pani, Annalisa Scopinaro, Sabine Vogler
    114-119
    DOI: https://doi.org/10.33393/grhta.2021.2278

  • The future of Funds for Innovative Medicines: results from a Delphi Study

    Claudio Jommi, Patrizio Armeni, Arianna Bertolani, Francesco Costa, Monica Otto
    22-28
    DOI: https://doi.org/10.33393/grhta.2021.2219

  • The AIFA time-to-reimbursement: a comparison between the last two committees from 2015 to 2020

    Paola Raimondo, Giorgio Casilli, Martina Isernia, Dario Lidonnici, Roberto Ravasio, Virginia Ronco, Elena Lanati
    109-114
    DOI: https://doi.org/10.33393/grhta.2020.2173

  • Valorization of clinical trials from the Italian National Health Service perspective: definition and first application of a model to estimate avoided costs

    Americo Cicchetti, Domenico Addesso, Filippo Elvino Leone, Antonino Amato, Luca Angerame, Angelo D'Aversa, Mario Fraticelli, Carlo Nicora, Eleonora Sfreddo, Mariangela Fumarola, Roberta Porcino, Gabriella Cocciolo, Simona Re, Sergio Scaccabarozzi
    26-32
    DOI: https://doi.org/10.33393/grhta.2020.709

  • Value-based healthcare: Il nuovo approccio di AIFA alla determinazione multidimensionale del valore AIFA’s new approach to multidimensional value determination

    Oriana Ciani, Carlo Federici, Giulia Fornaro, Carla Rognoni
    9-13
    DOI: https://doi.org/10.33393/grhta.2020.2102
26-50 of 35